Sanofi pays $180m for rights to Kali autoimmune drug
Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss
Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.
FDA seeks input into 'opaque' priority voucher scheme
FDA seeks public input on controversial priority voucher scheme amid concerns about its transparency and legality.
Dizal breaks new ground for EGFR drugs in lung cancer
Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey
The Industry’s Most Comprehensive End-to-End TCE Forum
The 8th T Cell Engager Therapeutics Summit is taking place June 23–25 in San Diego, CA,
The Evolution Summit Announces May 2026 Program for Clinical...
marcus evans announces The Evolution Summit, taking place May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida.
PHARMAP 2026: Where Pharma Meets Policy
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026)